Lymphoma News and Research

RSS

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

TGen and City of Hope announce letter of intent to develop new cell therapy manufacturing facility

City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute, have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered.

5 Nov 2018

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

Amgen today announced that new clinical data will be presented at the 60th American Society of Hematology Annual Meeting & Exposition in San Diego, Dec. 1-4, 2018. Data across an array of malignancies will be featured in 45 abstracts, including nine oral presentations, from the Company’s broad portfolio andearly-stage pipeline.

From AMGEN 5 Nov 2018

TGen, City of Hope to develop cell therapy manufacturing facility in Phoenix

City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute (TGen), have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered.

2 Nov 2018

UCLA researchers investigate how a protein factor contributes to cancer cell migration

UCLA researchers have discovered a new protein factor that contributes to a fibroblast cell's ability to migrate to a wound and participate in its healing process. The study's results could help scientists prevent cancer cells from using the same mechanisms to move throughout the body and spread.

1 Nov 2018

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Genentech, a member of the Roche Group , announced today that the randomized Phase III CLL14 study, which evaluated fixed-duration Venclexta® in combination with Gazyva® in people with previously untreated chronic lymphocytic leukemia and co-existing medical conditions, met its primary endpoint and showed a statistically significant reduction in the risk of disease worsening or death compared to standard-of-care Gazyva plus chlorambucil.

1 Nov 2018

Cytokine levels could predict autoimmune reactions to cancer immunotherapy

The development of immunotherapy, which mobilizes the body's own immune system to destroy cancer cells, is one of the greatest advances in cancer treatment, but immunotherapy can cause harm to healthy tissue in some patients.

31 Oct 2018

3 Harvard scientists receive Allen awards for work in neuroimmunology, developmental biology, cancer

Three Harvard Medical School scientists have received the prestigious Allen Distinguished Investigator awards for their work in the fields of neuroimmunology, developmental biology and cancer.

31 Oct 2018

Study shows how machinery within immune system activates T cells to attack cancer

In just a few years, CAR T-cell and other adoptive T-cell therapies have emerged as among the most promising forms of cancer immunotherapy.

31 Oct 2018

Scientists pinpoint TIM-3 protein as next potential target for immunotherapy treatments

Following the 2018 Nobel Prize for Medicine, global attention is now more than ever turned toward the promise of immunotherapy in oncology. An international team’s work has shed new light on a molecule called TIM-3 that might play a key role in the regulation of the immune response.

31 Oct 2018

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

Nanoparticles that could reprogram a cancer patient's immune system inside their own body. Understanding a mysterious type of brain cell in the hopes of shedding new light on Alzheimer's disease. Reimagining nuclei, the DNA-storage compartments of our cells, as miniature lava lamps.

30 Oct 2018

New approach may lead to protective vaccines for immunocompromised patients

A study led by Som Nanjappa at the University of Illinois College of Veterinary Medicine identifies a cellular target that may improve efficacy in vaccines designed to protect immunocompromised individuals from potentially deadly opportunistic infections.

26 Oct 2018

Head and neck cancer survivors more likely to commit suicide

Despite improved survival rates among cancer patients, the risk of death by suicide remains high, especially among those treated for head and neck cancers.

25 Oct 2018

Scientists identify new target for battling deadly form of leukemia

UT Southwestern scientists, working with colleagues at a sister institution in Houston, have identified a new target for battling a deadly form of leukemia.

24 Oct 2018

MIT researchers devise way to help blood cells regenerate after radiation therapy

Patients with blood cancers such as leukemia and lymphoma are often treated by irradiating their bone marrow to destroy the diseased cells. After the treatment, patients are vulnerable to infection and fatigue until new blood cells grow back.

24 Oct 2018

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Organic food may protect against cancers finds study

The study published this week in the latest issue of the journal JAMA Internal Medicine reports that people who consume more organic foods are at a lower overall risk of developing cancer compared to people who do not. Some of the specific cancers avoided are non-Hodgkin lymphoma and postmenopausal breast cancer write the researchers.

23 Oct 2018

Study findings could set new standard of care for advanced anal cancer

A new approach to treating advanced anal cancer is safer and more effective than the most widely used current treatment, according to the first ever randomized clinical trial in this group of patients.

22 Oct 2018

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Bristol-Myers Squibb Company today announced four-year data from the Phase 3 CheckMate -067 clinical trial - the longest follow-up to date - which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma.

22 Oct 2018

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Lymphoma News and Research

Further Reading

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

TGen and City of Hope announce letter of intent to develop new cell therapy manufacturing facility

Amgen announces presentation of new clinical data showcasing early oncology pipeline at ASH 2018

TGen, City of Hope to develop cell therapy manufacturing facility in Phoenix

UCLA researchers investigate how a protein factor contributes to cancer cell migration

Phase III CLL14 study evaluating Venclexta plus Gazyva to treat CLL meets its primary endpoint

Cytokine levels could predict autoimmune reactions to cancer immunotherapy

3 Harvard scientists receive Allen awards for work in neuroimmunology, developmental biology, cancer

Study shows how machinery within immune system activates T cells to attack cancer

Scientists pinpoint TIM-3 protein as next potential target for immunotherapy treatments

Ten Allen Distinguished Investigators for 2018 announced by Paul G. Allen Frontiers Group

New approach may lead to protective vaccines for immunocompromised patients

Head and neck cancer survivors more likely to commit suicide

Scientists identify new target for battling deadly form of leukemia

MIT researchers devise way to help blood cells regenerate after radiation therapy

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Organic food may protect against cancers finds study

Study findings could set new standard of care for advanced anal cancer

Combination of Opdivo and Yervoy shows four-year survival benefits in patients with advanced melanoma

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Everything you should know about lymphoma eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News